S2278 Safety of GLP-1 Agonists With Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis: Insights From a Phase 3 Study

Richard W. McCallum,Marilyn R. Carlson,David C. Kunkel
DOI: https://doi.org/10.14309/01.ajg.0001038480.66695.52
2024-10-26
The American Journal of Gastroenterology
Abstract:Metoclopramide nasal spray is US Food and Drug Administration (FDA)-approved for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Glucagon-like peptide 1 (GLP-1) receptor agonists, commonly used for diabetes and weight loss, may cause side effects such as nausea and vomiting due to their mechanism of action, which delays gastric emptying. Given the elimination half-life of these drugs, symptoms suggestive of gastroparesis may persist for weeks after discontinuation. This study aims to evaluate the safety of using metoclopramide nasal spray (MNS) concomitantly with GLP-1 drugs in women with diabetic gastroparesis and confirmed delayed gastric emptying.
gastroenterology & hepatology
What problem does this paper attempt to address?